Evolent Health Financial Statements (EVH)
|
|
|
|
Report date
|
|
|
02.03.2020 |
26.02.2021 |
24.02.2022 |
24.02.2023 |
23.02.2024 |
|
08.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
846.4 |
1 022 |
908.0 |
1 352 |
1 964 |
|
2 530 |
|
Operating Income, bln rub |
|
|
-120.4 |
-37.9 |
30.2 |
-59.8 |
-71.2 |
|
-17.3 |
|
EBITDA, bln rub |
? |
|
-245.9 |
-241.4 |
55.7 |
43.7 |
-24.8 |
|
63.0 |
|
Net profit, bln rub |
? |
|
-305.6 |
-334.2 |
-30.3 |
-18.7 |
-113.0 |
|
-70.1 |
|
|
OCF, bln rub |
? |
|
-42.6 |
-16.2 |
38.7 |
-11.6 |
142.6 |
|
63.7 |
|
CAPEX, bln rub |
? |
|
35.5 |
29.5 |
25.0 |
38.4 |
28.7 |
|
25.0 |
|
FCF, bln rub |
? |
|
-78.2 |
-45.7 |
13.8 |
-49.9 |
113.8 |
|
38.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
20.0 |
1.30 |
14.9 |
18.8 |
|
20.4 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-29.1% |
|
|
OPEX, bln rub |
|
|
453.7 |
372.0 |
279.5 |
336.5 |
531.7 |
|
329.9 |
|
Cost of production, bln rub |
|
|
513.1 |
701.4 |
657.6 |
1 035 |
1 503 |
|
2 217 |
|
R&D, bln rub |
|
|
19.8 |
15.1 |
15.5 |
27.0 |
0.000 |
|
13.0 |
|
Interest expenses, bln rub |
|
|
14.5 |
28.3 |
25.4 |
15.6 |
54.2 |
|
24.0 |
|
|
Assets, bln rub |
|
|
1 498 |
1 370 |
1 419 |
1 817 |
2 680 |
|
2 502 |
|
Net Assets, bln rub |
? |
|
922.4 |
619.6 |
693.6 |
859.4 |
1 068 |
|
1 039 |
|
Debt, bln rub |
|
|
368.8 |
359.8 |
280.5 |
476.1 |
644.8 |
|
635.2 |
|
Cash, bln rub |
|
|
101.0 |
340.5 |
266.3 |
188.2 |
192.8 |
|
112.9 |
|
Net debt, bln rub |
|
|
267.8 |
19.3 |
14.2 |
287.9 |
452.0 |
|
522.3 |
|
|
Ordinary share price, rub |
|
|
9.05 |
16.0 |
27.7 |
28.1 |
33.0 |
|
24.0 |
|
Number of ordinary shares, mln |
|
|
82.4 |
84.9 |
86.1 |
93.7 |
111.3 |
|
114.9 |
|
|
Market cap, bln rub |
|
|
745 |
1 361 |
2 381 |
2 631 |
3 675 |
|
2 753 |
|
EV, bln rub |
? |
|
1 013 |
1 381 |
2 396 |
2 919 |
4 127 |
|
3 276 |
|
Book value, bln rub |
|
|
42 |
-3 |
-12 |
-306 |
-801 |
|
-795 |
|
|
EPS, rub |
? |
|
-3.71 |
-3.94 |
-0.35 |
-0.20 |
-1.02 |
|
-0.61 |
|
FCF/share, rub |
|
|
-0.95 |
-0.54 |
0.16 |
-0.53 |
1.02 |
|
0.34 |
|
BV/share, rub |
|
|
0.51 |
-0.04 |
-0.14 |
-3.27 |
-7.20 |
|
-6.93 |
|
|
EBITDA margin, % |
? |
|
-29.1% |
-23.6% |
6.13% |
3.24% |
-1.26% |
|
2.49% |
|
Net margin, % |
? |
|
-36.1% |
-32.7% |
-3.34% |
-1.38% |
-5.76% |
|
-2.77% |
|
FCF yield, % |
? |
|
-10.5% |
-3.36% |
0.58% |
-1.90% |
3.10% |
|
1.40% |
|
ROE, % |
? |
|
-33.1% |
-53.9% |
-4.37% |
-2.18% |
-10.6% |
|
-6.74% |
|
ROA, % |
? |
|
-20.4% |
-24.4% |
-2.13% |
-1.03% |
-4.22% |
|
-2.80% |
|
|
P/E |
? |
|
-2.44 |
-4.07 |
-78.6 |
-140.7 |
-32.5 |
|
-39.3 |
|
P/FCF |
|
|
-9.53 |
-29.8 |
173.0 |
-52.7 |
32.3 |
|
71.3 |
|
P/S |
? |
|
0.88 |
1.33 |
2.62 |
1.95 |
1.87 |
|
1.09 |
|
P/BV |
? |
|
17.8 |
-424.6 |
-191.3 |
-8.59 |
-4.59 |
|
-3.46 |
|
EV/EBITDA |
? |
|
-4.12 |
-5.72 |
43.0 |
66.7 |
-166.5 |
|
52.0 |
|
Debt/EBITDA |
|
|
-1.09 |
-0.08 |
0.25 |
6.58 |
-18.2 |
|
8.29 |
|
|
R&D/CAPEX, % |
|
|
55.7% |
51.2% |
62.0% |
70.4% |
0.00% |
|
51.9% |
|
|
CAPEX/Revenue, % |
|
|
4.20% |
2.88% |
2.75% |
2.84% |
1.46% |
|
0.99% |
|
| Evolent Health shareholders |
